B+
Bull case
20%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
IMNN
ImunonBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
IMNN-001 has encouraging Phase 2 survival data, FDA-aligned Phase 3 design, and reported ahead-of-plan OVATION 3 enrollment. Successful confirmation could materially re-rate the stock from its $1.59 anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Analyst target count, options data, short interest, and social sentiment coverage are unavailable.
Momentum
93
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.60 · Bull $3.00 · Bear $0.70Analysis 2026-07-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum93 · Δ7d -
Value41 · Δ7d -0.0
Sentiment75 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Analyst target count, options data, short interest, and social sentiment coverage are unavailable.
- • Enrollment is expected to complete only by Q1 2029, creating substantial duration and execution risk.
- • The company remains a roughly $6.7 million micro-cap with a long Phase 3 timeline, financing and dilution exposure, and unproven Phase 3 efficacy.
Catalyst clock
2026-09-30
Financing and cash-burn sensitivity
Lead driver: Sentiment · See AI snapshot
Momentum
93
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
75
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 93.5 / Value 41.2 / Sentiment 75.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-22. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$8.98M
Beta
2.13
Shares Out
5.61M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.40
Rev YoY
-100.0%
EPS YoY
-71.0%
Gross Margin
-387.2%
Op Margin
-
Net Debt
-$7.77M
Current Ratio
1.82
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data